Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders
Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders
批准号:
10012998
负责人:
Rene Anand
金额:
$24.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-01 至 2020-10-31
关键词:
Alcohol or Other Drugs useAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAntidotesAutopsyBig DataBiological MarkersBiological ModelsBrainBrain DiseasesBusinessesCell LineCellsCentral Nervous System DiseasesCerebrumClientClinicClinicalClinical ResearchComplexDataData CollectionDependenceDerivation procedureDevelopmentDiagnosticDiagnostic testsDiseaseDrug AddictionDrug ExposureEmbryoEngineeringExhibitsFacultyFeedbackFutureGene ExpressionGenesGenetic TranscriptionGenotypeGoalsHumanHuman Cell LineIn VitroInnate Immune ResponseIntellectual PropertyLegal patentLinkMedical DeviceMedicineMethodologyMicrogliaMidbrain structureModelingMolecularOperative Surgical ProceduresOpioidOrganoidsOutputPathway AnalysisPatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePhasePreclinical TestingPredispositionProcessRegulator GenesReportingReproducibilityRetinaRodent ModelSafetySamplingSchizophreniaSkinSmall Business Innovation Research GrantSpinal CordStructureSubstance Abuse DetectionSubstance abuse problemSystemTechnologyTestingTimeToxicity TestsUnited States National Institutes of HealthUniversitiesValidationbasebrain cellcell immortalizationcell typeclinical applicationcommercializationcostdata modelingdisease mechanisms studydisease phenotypedrug developmentdrug discoverydrug of abuseearly detection biomarkersefficacy testinghindbraininduced pluripotent stem cellmathematical modelopioid use disorderpersonalized predictionspre-clinicalprospectiverelating to nervous systemresponsesafety testingscreeningsubstance abuse treatmenttherapeutic targettranscriptomicstranslational medicinetranslational neuroscience
中文摘要
这是来自神经系统公司的SBIR提案,该公司被NCET2选为“最佳大学”
英文摘要
This is a SBIR proposal from Neurxstem Inc., a company selected by NCET2 as a “Best University
Startups 2016” is in response to the NIH HEAL initiative. Neurxstem’s goals are to develop and
optimize a proprietary induced pluripotent stem cell derived human Neural Organoid Platform
(NNOP) to develop 1) an early diagnostic NNOP for substance (SUD) and opioid (OUD) use
disorder susceptibility and 2) to identify early therapeutic targets for future screens for effective
SUD/OUD disease-related drug discovery, efficacy and safety screening. The current state of the
art technology for such goals ranges from human primary and immortalized cell lines to rodent
models. Because these models are poor surrogates for the complex network structure of the
human brain, the proposed platform is expected to fill a crucial gap in translational neuroscience
goals to understand and treat human brain disorders. Neurxstem has developed the proprietary
methodology to make nearly complete human neural organoids and has shown that a superior
NNOP compared to other ‘organoids’ that has all the major parts of the brain – retina, cortex,
midbrain, hindbrain, and spinal cord - in a single, networked and scalable NNOP that also
expresses all the major cell types including the microglia critically involved in SUD and exhibits
responses to a drug of addiction that alters a multitude of biomarkers linked to multiple drugs of
abuse. Neurxstem, a small business founded by Dr. Rene Anand, one of the technology
inventors, proposes to further develop this clinically corroborated model system to test its
reliability, reproducibility, robustness and utility for commercial translational neuroscience
applications for SUD/OUD and initiate market entry after FDA approval. Phase I Aims: The
Phase I goals are to identify early therapeutic targets by: 1) mathematical modeling of gene
expression data responses to drugs of addiction to deduce early biomarkers for SUD/OUD. Phase
II Aims: One goal is identify all possible early therapeutic targets by mathematical modeling from
multiple data points and drug exposure samples for future SUD/OUD countermeasure
development with Pharma. A second goal is to scale and validate the platform with multiple SUD
patient iPSC lines to demonstrate: a) reliability, b) reproducibility and c) robustness metrics
needed to demonstrate the full utility for early diagnostic and drug discovery, efficacy and safety
testing commercial goals for SUD/OUD. Additionally, Neuxstem’s commercialization plan
includes 1) market feedback from prospective clients for product validation; 2) initial market entry
with beta customers/ business partners; and 3) continuing intellectual property development and
prosecution. Fundamentally, the further development and validation of Neurxstem’s NNOP
should provide a lower cost, more precise and accurate system for personalized, predictive
diagnostic medicine and development of countermeasure for SUD/OUD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders
-
批准号:10307375
-
项目类别:
-
资助金额:$107.19万
-
财政年份:2020
-
负责人:Rene Anand
-
依托单位:
Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders
-
批准号:10341232
-
项目类别:
-
资助金额:$44.51万
-
财政年份:2020
-
负责人:Rene Anand
-
依托单位:
Fish Electric Organ as a Factory for Membrane Proteins
-
批准号:7910390
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2009
-
负责人:Rene Anand
-
依托单位:
Fish Electric Organ as a Factory for Membrane Proteins
-
批准号:8310108
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2009
-
负责人:Rene Anand
-
依托单位:
Fish Electric Organ as a Factory for Membrane Proteins
-
批准号:8119554
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2009
-
负责人:Rene Anand
-
依托单位:
Modulation of Nicotinic Receptors by Cytosolic Proteins
-
批准号:7455290
-
项目类别:
-
资助金额:$28.55万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Modulation of Nicotinic Receptors by Cytosolic Proteins
-
批准号:7390195
-
项目类别:
-
资助金额:$23.96万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Proteomics of Nicotinic Receptor Complexes
-
批准号:7390196
-
项目类别:
-
资助金额:$16.4万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Modulation of Nicotinic Receptors by Cytosolic Proteins
-
批准号:7633281
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Modulation of Nicotinic Receptors by Cytosolic Proteins
-
批准号:7837671
-
项目类别:
-
资助金额:$30.04万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Proteomics of Nicotinic Receptor Complexes
-
批准号:7230264
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Proteomics of Nicotinic Receptor Complexes
-
批准号:7101349
-
项目类别:
-
资助金额:$1.39万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
Modulation of Nicotinic Receptors by Cytosolic Proteins
-
批准号:7284212
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:Rene Anand
-
依托单位:
TOPOLOGY & STOICHIOMETRY OF GLUTAMATE RECEPTOR SUBUNITS
-
批准号:2609671
-
项目类别:
-
资助金额:$9.84万
-
财政年份:1994
-
负责人:Rene Anand
-
依托单位:
TOPOLOGY & STOICHIOMETRY OF GLUTAMATE RECEPTOR SUBUNITS
-
批准号:2839374
-
项目类别:
-
资助金额:$9.92万
-
财政年份:1994
-
负责人:Rene Anand
-
依托单位:
TOPOLOGY & STOICHIOMETRY OF GLUTAMATE RECEPTOR SUBUNITS
-
批准号:2037878
-
项目类别:
-
资助金额:$11.01万
-
财政年份:1994
-
负责人:Rene Anand
-
依托单位:
TOPOLOGY & STOICHIOMETRY OF GLUTAMATE RECEPTOR SUBUNITS
-
批准号:2272527
-
项目类别:
-
资助金额:$11.34万
-
财政年份:1994
-
负责人:Rene Anand
-
依托单位:
TOPOLOGY & STOICHIOMETRY OF GLUTAMATE RECEPTOR SUBUNITS
-
批准号:2272526
-
项目类别:
-
资助金额:$11.12万
-
财政年份:1994
-
负责人:Rene Anand
-
依托单位: